A randomized trial of cytarabine with high-dose mitoxantrone compared to a standard vincristine/prednisone-based regimen as induction therapy for adult patients with ALL.

被引：0
|
作者：
Weiss, MA
Heffner, L
Lamanna, N
Kalaycio, M
Schiller, G
Coutre, S
Maslak, P
Jurcic, J
Panageas, K
Scheinberg, DA
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Emory Univ, Atlanta, GA 30322 USA
[3] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[4] Univ Calif Los Angeles, Los Angeles, CA USA
[5] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：564S / 564S
页数：1
相关论文
共 50 条
  • [41] Randomized controlled trial of standard versus high-dose intravenous omeprazole after endoscopic therapy in high-risk patients with acute peptic ulcer bleeding
    Chan, W. H.
    Khin, L. W.
    Chung, Y. F. A.
    Goh, Y. C.
    Ong, H. S.
    Wong, W. K.
    BRITISH JOURNAL OF SURGERY, 2011, 98 (05) : 640 - 644
  • [42] High-dose mitoxantrone-based induction therapy in newly diagnosed AML. Results of 171 patients treated at NYMC between 1991-2003.
    Seiter, K
    Liu, D
    Feldman, E
    Shi, Q
    Qureshi, A
    Baskind, P
    Arshad, M
    Ahmed, T
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 585S - 585S
  • [43] 6-thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML):: A randomized trial of the German AML cooperative group
    Büchner, T
    Hiddemann, W
    Berdel, WE
    Wörmann, B
    Schoch, C
    Fonatsch, C
    Löffler, H
    Haferlach, T
    Ludwig, WD
    Maschmeyer, G
    Staib, P
    Aul, C
    Grüneisen, A
    Lengfelder, E
    Frickhofen, N
    Kern, W
    Serve, HL
    Mesters, RM
    Sauerland, MC
    Heinecke, A
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) : 4496 - 4504
  • [44] High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia - Results of an international multicenter randomized trial
    Jaksic, B
    Brugiatelli, M
    Krc, I
    Losonczi, H
    Holowiecki, J
    PlanincPeraica, A
    Kusec, R
    Morabito, F
    Iacopino, P
    Lutz, D
    CANCER, 1997, 79 (11) : 2107 - 2114
  • [45] High-dose mitoxantrone-based induction therapy in newly-diagnosed AML. Results of 171 patients treated at NYMC between 1991-2003.
    Seiter, K
    Liu, DL
    Feldman, E
    Shi, QH
    Baskind, P
    Arshad, M
    Qureshi, A
    Ahmed, T
    BLOOD, 2005, 106 (11) : 529A - 529A
  • [46] Induction Treatment In Elderly Patients with Acute Myeloid Leukemia (AML): Randomized Comparison of Intermediate-Dose Cytarabine Plus Mitoxantrone (IMA) Versus Standard-Dose Cytarabine Plus Daunorubicin (DA) In 492 AML Patients >60 Years - Results From the SAL 60plus Trial
    Rollig, Christoph
    Kramer, Michael
    Hanel, Mathias
    Herbst, Regina
    Schmitz, Norbert
    Bodenstein, Heinrich
    Pflueger, Karl-Heinz
    Wagner, Thomas
    Wolf, Martin
    Bornhaeuser, Martin
    Thiede, Christian
    Schaich, Markus
    Platzbecker, Uwe
    Stoelzel, Friedrich
    von Bonin, Malte
    Wandt, Hannes
    Ehninger, Gerhard
    Schuler, Ulrich
    BLOOD, 2010, 116 (21) : 151 - 152
  • [47] High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia
    Rea, D
    Legros, L
    Raffoux, E
    Thomas, X
    Turlure, P
    Maury, S
    Dupriez, B
    Pigneux, A
    Choufi, B
    Reman, O
    Stéphane, D
    Royer, B
    Vigier, M
    Ojeda-Uribe, M
    Recher, C
    Dombret, H
    Huguet, F
    Rousselot, P
    LEUKEMIA, 2006, 20 (03) : 400 - 403
  • [48] High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia
    D Rea
    L Legros
    E Raffoux
    X Thomas
    P Turlure
    S Maury
    B Dupriez
    A Pigneux
    B Choufi
    O Reman
    D Stéphane
    B Royer
    M Vigier
    M Ojeda-Uribe
    C Recher
    H Dombret
    F Huguet
    P Rousselot
    Leukemia, 2006, 20 : 400 - 403
  • [49] High-dose induction vs standard dosage interferon alpha (IFN α) in naive hepatitis C (HCV) patients -: Preliminary analysis of a multicenter, randomized controlled trial.
    Flamm, S
    Conjeevarum, H
    Wiley, T
    Ganger, D
    O'Riordan, K
    HEPATOLOGY, 1998, 28 (04) : 282A - 282A
  • [50] A multicenter randomized trial comparing response-adapted (RA), non-gross-resistant indication and consolidation with idarubicin/cytarabine (IDAC) followed by mitoxantrone/etoposide (NOVE) compared with consolidation with high dose cytarabine (HDAC) in adult patients with AML. A study by the Canadian Leukemia Studies Group (CLSG).
    van der Jagt, RHC
    Robinson, KS
    Sheridan, DP
    Delage, R
    Larratt, LM
    Yetisir, L
    Wells, GA
    Belch, A
    BLOOD, 2002, 100 (11) : 344A - 344A
12345